Sifat Sharmin, Izanne Roos, Charles B Malpas, Pietro Iaffaldano, Marta Simone, Massimo Filippi, Eva Kubala Havrdova, Serkan Ozakbas, Vincenzo Brescia Morra, Raed Alroughani, Mauro Zaffaroni, Francesco Patti, Sara Eichau, Giuseppe Salemi, Alessia Di Sapio, Matilde Inglese, Emilio Portaccio, Maria Trojano, Maria Pia Amato, Tomas Kalincik
BACKGROUND: High-efficacy disease-modifying therapies have been proven to slow disability accrual in adults with relapsing-remitting multiple sclerosis. However, their impact on disability worsening in paediatric-onset multiple sclerosis, particularly during the early phases, is not well understood. We evaluated how high-efficacy therapies influence transitions across five disability states, ranging from minimal disability to gait impairment and secondary progressive multiple sclerosis, in people with paediatric-onset multiple sclerosis...
March 21, 2024: Lancet Child & Adolescent Health